Clinical Trials Logo

Papulopustular Rosacea clinical trials

View clinical trials related to Papulopustular Rosacea.

Filter by:

NCT ID: NCT03564145 Terminated - Clinical trials for Papulopustular Rosacea

A Long-Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Start date: September 12, 2018
Phase: Phase 3
Study type: Interventional

To assess the safety of S5G4T-1 when applied once daily for up to 40 weeks in participants with papulopustular rosacea who completed either Study SGT-54-01 (NCT03448939) or Study SGT-54-02 (NCT03564119).

NCT ID: NCT03564119 Completed - Clinical trials for Papulopustular Rosacea

A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

Start date: June 21, 2018
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of S5G4T-1 compared to S5G4T-1 vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.

NCT ID: NCT03448939 Completed - Clinical trials for Papulopustular Rosacea

A Study of S5G4T-1 in the Treatment of Papulopustular Rosacea

Start date: June 18, 2018
Phase: Phase 3
Study type: Interventional

To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.

NCT ID: NCT03276936 Completed - Clinical trials for Papulopustular Rosacea

A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea

Start date: September 5, 2017
Phase: Phase 3
Study type: Interventional

The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.

NCT ID: NCT03263273 Completed - Rosacea Clinical Trials

Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea

Start date: October 30, 2017
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy of once-daily application of 1% and 3% HY01 Topical Gel, as assessed by the change in inflammatory lesion count from baseline over the 12-week treatment period in patients with moderate-to-severe papulopustular rosacea.

NCT ID: NCT03079531 Completed - Clinical trials for Papulopustular Rosacea

Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Start date: June 21, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.

NCT ID: NCT02601963 Completed - Rosacea Clinical Trials

Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular Rosacea

EMIRA
Start date: September 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if the study drug, FMX-103, is safe to give and if it helps people with moderate-to-severe papulopustular rosacea. The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied along with vehicle. The foam will be applied once daily to the face for the 12-week treatment duration of the study. Approximately 210 patients will participate in this study.

NCT ID: NCT02393937 Completed - Clinical trials for Papulopustular Rosacea

A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea

Start date: February 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy of two Metronidazole Gels 1%, in the treatment of Rosacea.

NCT ID: NCT02268474 Completed - Clinical trials for Papulopustular Rosacea

Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea

Start date: September 2014
Phase: N/A
Study type: Interventional

A single center prospective, randomized, controlled split face study comparing a 532nm KTP laser with a 595nm PDL for the treatment of Erythematotelangiectatic Rosacea and Papulopustular Rosacea. Subjects will receive laser treatments and will be followed at 6 weeks post-final laser treatment.

NCT ID: NCT02075671 Completed - Rosacea Clinical Trials

Photodynamic Therapy for Papulopustular Rosacea

Start date: April 24, 2014
Phase: Phase 4
Study type: Interventional

Rosacea is a chronic inflammatory disorder that is characterized by severe flushing (transient erythema), non-transient erythema, papules, pustules, and telangiectasia. Topical therapy is not always effective in treating symptoms of rosacea. Furthermore, rapid recurrence is common following the use of systemic antibiotics, resulting in the chronic use of these medications to control the disease. Although the exact pathogenesis of rosacea is unknown, treatment for this condition has been investigated based on its similarity to acne and photodamaged skin. Case reports have shown promising results in rosacea patients treated with methyl aminolevulinate photodynamic therapy (MAL - PDT). Other than a case report which observed significant improvement of papules, pustules, erythema, and flushing following 5 - aminolevulinic acid photodynamic therapy (ALA-PDT) treatment of a patient with rosacea, the role of ALA-PDT in the treatment of rosacea has not been reported. We have designed a pilot study investigating the efficacy of ALA-PDT in treating papulopustular rosacea. The objectives of the study are as follows: Primary objective: 1. To evaluate improvement of the inflammatory lesions (papules, pustules, nodules), erythema, and telangiectasia of rosacea as assessed by the Investigator's Global Assessment (IGA). 2. To evaluate improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as assessed by the Inflammatory Lesion Investigator's Global Assessment (ILIGA). Secondary objectives: 3. To evaluate improvement of rosacea associated erythema as assessed by the Clinical Erythema Assessment (CEA) scale. 4. To evaluate improvement of the inflammatory lesions (papules, pustules, nodules) of rosacea as measured by a difference in inflammatory lesion count. 5. To evaluate improvement of rosacea as assessed by the Patient Overall Assessment Scale.